Please login to the form below

Not currently logged in
Email:
Password:

Novartis announces departures of three execs

Follows deals to sell divisions to GSK and Lilly

Novartis George GunnNovartis Brian McNamaraNovartis Andrin Oswald

George Gunn, Brian McNamara and Andrin Oswald

Three senior executives at Novartis are to leave the company in the wake of multibillion dollar deals the company agreed with GlaxoSmithKline (GSK) and Lilly earlier this year that effectively make their roles redundant.

George Gunn, head of Novartis animal health; Brian McNamara, head of Novartis OTC; and Andrin Oswald, head of Novartis vaccines, will all leave the Switzerland-based company once the transactions are completed in the first half of 2015.

The deals, which were agreed in April, will see Novartis acquire GSK's oncology business, with its vaccines division going in the other direction. GSK and Novartis also intend to combine their consumer health businesses, while a separate deal will see Lilly acquire Novartis' animal health division for $5.4bn.

Gunn, who joined Novartis in 2003 as head of animal health in North America, will retire once the deal with Lilly is complete. Oswald – who was also chairman of the board of the Novartis Foundation for Sustainable Development - will also leave the company completely, with Novartis stating he intends to “pursue other opportunities”.

As for McNamara – a ten-year veteran of Novartis OTC - he will move to GSK where he will become head of Americas and Europe for the combined consumer health businesses once the deal is finalised. He will report to GSK's president of consumer healthcare.

9th October 2014

From: Research, Sales

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

Lifting the fog to help Clinical Labs navigate IVDR 2022
In Vitro Diagnostic Regulation (IVDR 2022) was on the horizon: a new regulatory basis for laboratories to adhere to regarding their diagnostic equipment and tests. BD wanted to let their...
Empowering adolescents to manage emotional and mental health issues
1 in 10 UK children suffer with a mental health issue and alarmingly as many as 70% of these don’t receive the proper support they need. That’s why The Anna...
Reframing rare to increase earlier diagnosis of Gaucher Disease
Sanofi Genzyme wanted to reach haematologists; the specialist physicians most likely to encounter patients with Gaucher Disease prior to diagnosis. The problem? Gaucher Disease is considered very rare and its...